The AI-focused drug developer received cash from new and existing investors that could include Lundbeck and Upsher-Smith Laboratories.
BenevolentAI, a UK-based, healthcare-focused artificial intelligence technology developer backed by pharmaceutical companies Lundbeck and Upsher-Smith Laboratories, raised $115m today from unnamed new and existing investors at a $2bn pre-money valuation.
The only participant named in the round, which the company said increased its overall funding to more than $200m, was fund manager Woodford Investment Management.
Founded in 2013, BenevolentAI is using AI technology to discover drug molecules that can be developed into drugs for diseases that are difficult to treat,…
